Vertex Pharmaceuticals Incorporated
VRTX
$434.07
$4.471.04%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.59% | 15.66% | 11.61% | 6.11% | 13.30% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.96% | 15.66% | 11.61% | 6.11% | 13.30% |
| Cost of Revenue | 18.64% | 5.41% | 12.39% | 22.32% | 12.11% |
| Gross Profit | -8.43% | 24.89% | 10.97% | -6.56% | 14.18% |
| SG&A Expenses | 15.67% | -6.53% | 40.94% | 41.74% | 42.14% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 17.95% | 2.59% | 17.80% | 26.07% | 17.90% |
| Operating Income | -15.22% | 37.02% | 3.72% | -17.72% | 8.18% |
| Income Before Tax | -42.90% | -0.97% | 3.81% | -391.97% | 43.48% |
| Income Tax Expenses | -53.15% | 25.00% | 24.18% | -17.66% | -6.36% |
| Earnings from Continuing Operations | -41.22% | -5.76% | 0.98% | -492.44% | 57.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.22% | -5.76% | 0.98% | -492.44% | 57.13% |
| EBIT | -15.22% | 37.02% | 3.72% | -17.72% | 8.18% |
| EBITDA | -14.98% | 32.70% | 4.56% | -16.03% | 9.17% |
| EPS Basic | -40.93% | -5.69% | 0.97% | -491.83% | 56.64% |
| Normalized Basic EPS | -15.19% | 27.15% | -0.14% | -15.27% | 10.08% |
| EPS Diluted | -40.86% | -5.64% | 1.01% | -495.55% | 56.51% |
| Normalized Diluted EPS | -15.09% | 27.25% | -0.29% | -14.39% | 10.08% |
| Average Basic Shares Outstanding | -0.50% | -0.08% | 0.00% | 0.16% | 0.31% |
| Average Diluted Shares Outstanding | -0.61% | -0.15% | 0.15% | -0.88% | 0.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |